GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Return-on-Tangible-Asset

Revelation Biosciences (FRA:56U0) Return-on-Tangible-Asset : -79.82% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Revelation Biosciences's annualized Net Income for the quarter that ended in Mar. 2024 was €-9.87 Mil. Revelation Biosciences's average total tangible assets for the quarter that ended in Mar. 2024 was €12.36 Mil. Therefore, Revelation Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -79.82%.

The historical rank and industry rank for Revelation Biosciences's Return-on-Tangible-Asset or its related term are showing as below:

FRA:56U0' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -359.86   Med: -287.08   Max: -1.35
Current: -59.5

During the past 4 years, Revelation Biosciences's highest Return-on-Tangible-Asset was -1.35%. The lowest was -359.86%. And the median was -287.08%.

FRA:56U0's Return-on-Tangible-Asset is ranked worse than
63.74% of 1547 companies
in the Biotechnology industry
Industry Median: -40.12 vs FRA:56U0: -59.50

Revelation Biosciences Return-on-Tangible-Asset Historical Data

The historical data trend for Revelation Biosciences's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Return-on-Tangible-Asset Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
- -378.52 -292.03 -1.34

Revelation Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 208.08 -33.71 -70.03 -65.90 -79.82

Competitive Comparison of Revelation Biosciences's Return-on-Tangible-Asset

For the Biotechnology subindustry, Revelation Biosciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revelation Biosciences's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's Return-on-Tangible-Asset falls into.



Revelation Biosciences Return-on-Tangible-Asset Calculation

Revelation Biosciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-0.11/( (5.195+11.199)/ 2 )
=-0.11/8.197
=-1.34 %

Revelation Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-9.868/( (11.199+13.526)/ 2 )
=-9.868/12.3625
=-79.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Revelation Biosciences  (FRA:56U0) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Revelation Biosciences Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Revelation Biosciences (FRA:56U0) Business Description

Traded in Other Exchanges
Address
4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines